Back to top
more

Bristol Myers Squibb (BMY)

(Delayed Data from NYSE)

$47.81 USD

47.81
9,409,499

-0.04 (-0.08%)

Updated Aug 14, 2025 04:00 PM ET

After-Market: $47.86 +0.05 (0.10%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value D Growth D Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 41% (146 out of 246)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

New York-based Bristol-Myers Squibb is a one of the leading global specialty bio-pharmaceutical companies focused on the development of treatments targeting serious diseases. Backed by its blockbuster immune-oncology drug, Opdivo, Bristol-Myers has a strong oncology portfolio, consisting of other drugs like Revlimid, Sprycel, Yervoy and Empliciti. Beyond oncology, the company has important immunology and cardiovascular drugs like Orencia and Eliquis, which diversify its portfolio. Notably, in the cardiovascular space, Eliquis is now the global leading oral anti-coagulant drug. The company continues to experience growth in both the Eliquis brand and the market, while also advancing its Factor XIa inhibitor program..

Zacks Equity Research

Exelixis' (EXEL) IND for Oncology Candidate Accepted by FDA

by Zacks Equity Research

The FDA accepts Exelixis' (EXEL) IND for XB002 in patients with advanced solid tumors and a phase I study is expected to start in the second quarter.

Zacks Equity Research

Is Bristol Myers Squibb (BMY) Outperforming Other Medical Stocks This Year?

by Zacks Equity Research

Is (BMY) Outperforming Other Medical Stocks This Year?

Zacks Equity Research

Exelixis (EXEL) Partner Gets EC Nod for Cabometyx + Opdivo

by Zacks Equity Research

Exelixis' (EXEL) partner Ipsen secures an approval from the regulatory body in Europe for the combination of Cabomteyx and Opdivo to treat first-line RCC.

Zacks Equity Research

Sanofi (SNY) Gets FDA Approval for Sarclisa Label Expansion

by Zacks Equity Research

Sanofi's (SNY) Sarclisa gets FDA approval to treat multiple myeloma patients who have received one to three prior lines of therapy in combination with Kyprolis and dexamethasone.

Zacks Equity Research

Amgen (AMGN) to Boost Inflammation Pipeline With Rodeo Buyout

by Zacks Equity Research

Amgen (AMGN) inks an agreement to acquire privately held company, Rodeo Therapeutics Corporation, to boost its inflammation portfolio.

Zacks Equity Research

Biotech Stock Roundup: BLUE/BMY's CAR T Therapy Nod, KLDO's COVID-19 Study News & More

by Zacks Equity Research

The biotech sector gains prominence with new product approvals from bluebird (BLUE)/Bristol Myers Squibb (BMY) and other coronavirus updates.

Zacks Equity Research

bluebird (BLUE), Bristol Myers CAR T Cell Therapy Gets FDA Nod

by Zacks Equity Research

bluebird (BLUE) and partner Bristol Myers clinch an FDA approval for their chimeric antigen receptor T cell immunotherapy Abecma to address relapsed or refractory multiple myeloma.

Zacks Equity Research

Bristol Myers Squibb (BMY) Gains As Market Dips: What You Should Know

by Zacks Equity Research

In the latest trading session, Bristol Myers Squibb (BMY) closed at $64.07, marking a +0.2% move from the previous day.

Zacks Equity Research

Bristol-Myers (BMY) Announces Results From Opdivo Combo Study

by Zacks Equity Research

Bristol-Myers (BMY) announces encouraging primary results from a study, evaluating a fixed-dose combination of relatlimab and immuno-oncology drug, Opdivo, in metastatic or unresectable melanoma.

Zacks Equity Research

Bristol Myers Squibb (BMY) Outpaces Stock Market Gains: What You Should Know

by Zacks Equity Research

In the latest trading session, Bristol Myers Squibb (BMY) closed at $63.38, marking a +1.08% move from the previous day.

Zacks Equity Research

Roche's (RHHBY) Tecentriq Meets Primary Goal in Lung Cancer Study

by Zacks Equity Research

Roche's (RHHBY) Tecentriq meets primary endpoint of disease-free survival at the interim analysis in lung cancer patients.

Zacks Equity Research

Bristol Myers' (BMY) NDA for Mavacamten Accepted by FDA

by Zacks Equity Research

The FDA accepts Bristol Myers' (BMY) new drug application for mavacamten for treating patients with symptomatic obstructive hypertrophic cardiomyopathy.

Zacks Equity Research

J&J's (JNJ) Multiple Sclerosis Drug Ponesimod Gets FDA Nod

by Zacks Equity Research

J&J's (JNJ) ponesimod demonstrated superior clinical efficacy in reducing annual relapses compared to Sanofi's Aubagio in clinical studies.

Zacks Equity Research

Corcept (CORT) Begins Adrenal Cancer Study on Relacorilant

by Zacks Equity Research

Corcept (CORT) commences phase Ib study on relacorilant in combination with Keytruda for treating patients with adrenal cancer with cortisol excess.

Zacks Equity Research

Bristol Myers Squibb (BMY) Outpaces Stock Market Gains: What You Should Know

by Zacks Equity Research

In the latest trading session, Bristol Myers Squibb (BMY) closed at $61.39, marking a +1.24% move from the previous day.

Zacks Equity Research

AVEO Collaborates with Bristol Myers to Conduct Combo Study

by Zacks Equity Research

AVEO forges an alliance with Bristol Myers to evaluate Fotivda in combination with Opdivo for RCC.

Zacks Equity Research

AnaptysBio (ANAB) Plunges on Lead Candidate Study Failure

by Zacks Equity Research

AnaptysBio's (ANAB) lead pipeline candidate, imsidolimab, fails to meet primary endpoint of a mid-stage study evaluating it in patients with auto-inflammatory disease, palmoplantar pustulosis.

Kaustav Ghosh headshot

5 Stocks to Watch Amid Continued Expansion in the Biotech Industry

by Kaustav Ghosh

The biotech industry seems poised for further growth due to factors like advancements in drug research and faster regulatory process, making it wise to look at names like AbbVie (ABBV) and Novavax (NVAX)

Zacks Equity Research

Roche (RHHBY) Withdraws Bladder Cancer Indication for Tecentriq

by Zacks Equity Research

Roche (RHHBY) voluntarily withdraws the bladder cancer indication of Tecentriq in the United States.

Zacks Equity Research

Gilead's (GILD) CAR T Cell Therapy Yescarta Gets FDA Nod for FL

by Zacks Equity Research

Gilead's (GILD) CAR T-cell therapy gets a boost with the FDA approval of Yescarta for the treatment of adult patients with relapsed or refractory follicular lymphoma.

Zacks Equity Research

The Zacks Analyst Blog Highlights: Mastercard, NVIDIA, Costco, Disney and Bristol-Myers Squibb

by Zacks Equity Research

The Zacks Analyst Blog Highlights: Mastercard, NVIDIA, Costco, Disney and Bristol-Myers Squibb

Zacks Equity Research

Why Is Bristol Myers (BMY) Down 1.8% Since Last Earnings Report?

by Zacks Equity Research

Bristol Myers (BMY) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Sheraz Mian headshot

Top Stock Reports for Mastercard, NVIDIA & Costco

by Sheraz Mian

Today's Research Daily features new research reports on 16 major stocks, including Mastercard (MA), NVIDIA (NVDA), and Costco (COST).

Zacks Equity Research

Amgen (AMGN) to Add Stomach Cancer Drug With Five Prime Buyout

by Zacks Equity Research

Amgen (AMGN) inks a $1.9-billion deal to acquire clinical-stage biotech, Five Prime Therapeutics, to boost its oncology pipeline.

Sweta Killa headshot

ETFs to Tap Amgen's Drive for Cancer Deal

by Sweta Killa

Amgen (AMGN) has agreed to buy Five Prime Therapeutics (FPRX) for $1.9 billion.